# Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

> **NCT02387606** · PHASE2 · COMPLETED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 66 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** Placebo
- **DRUG:** JNJ-53718678

## Key facts

- **NCT ID:** NCT02387606
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-07
- **Primary completion:** 2015-09-21
- **Final completion:** 2015-10-02
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2022-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02387606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02387606, "Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02387606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*